Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Tri...

by Azuma, M., Ikeda, S., Ishii, M., Izumi, N., Kaneko, S., Kobayashi, M., Kudo, M., Meier, G., Pan, J.
Published 2021

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

by Breder, V., Cheng, A.-L, Ducreux, M., Finn, R.S, Galle, P.R, Ikeda, M., Kaseb, A.O, Kim, T.-Y, Kudo, M., Li, D., Li, L., Lim, H.Y, Ma, N., Merle, P., Nicholas, A., Qin, S., Verret, W., Wang, Y., Zhu, A.X
Published 2022

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

by Cattan, S., Chan, S.L, Cheng, A.-L, Daniele, B., Edeline, J., Fartoux, L., Finn, R.S, Gurary, E.B, KEYNOTE-224 Investigators, Knox, J., Kudo, M., Ogasawara, S., Palmer, D.H, Sarker, D., Siegel, A.B, Verset, G., Verslype, C., Vogel, A., Wang, A., Yau, T., Zagonel, V., Zhu, A.X
Published 2022